Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symptom Burden Reduction in NSCLC Chemoradiation
NCT01048983Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of armodafinil, bupropion, curcumin and minocycline in non-small cell lung cancer (NSCLC) (16 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Combined Area Under the Curve for Selected Symptoms at 10 weeks. Status: withdrawn.
02
Drugs
armodafinilbupropioncurcuminminocycline
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01048983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01048983.